incomplete Freund's adjuvant

02/01/2004 - "In total, among mice immunized with yMSP1(19), 22 of 32 (68.7%) with ISA plus CpG 1826, 0 of 4 (0%) with CFA/incomplete Freund's adjuvant, 0 of 4 (0%) with CpG 1826 mixed with ISA (no yMSP1(19)), and 0 of 11 (0%) with CpG 1826 alone were completely protected against development of erythrocytic stage infection after sporozoite challenge. "
07/01/1995 - "By varying dose, route, and frequency of LCMV GP peptide application, we found that a single local subcutaneous injection of 50-500 micrograms peptide emulsified in incomplete Freund's adjuvant protected mice against LCMV infection, whereas repetitive and systemic intraperitoneal application of the same dose caused tolerance of LCMV-specific CTL. "
09/01/1963 - "1963.-Some protection to chronic candidiasis in mice was produced by sublethal intraperitoneal infection with Candida albicans and by the injection in incomplete Freund's adjuvant of nonviable Coccidioides immitis spherule fragments. "
09/07/1998 - "Immunization of mice with this rBCG induced a higher degree of protection against blood-stage parasite infection than with recombinant MSP1-15 in the RIBI adjuvant (RIBI ImmunoChem Research, Inc., Hamilton, MT) or incomplete Freund's adjuvant systems. "
01/01/1976 - "minnesota antigen in combination with incomplete Freund's adjuvant provided substantial protection against an otherwise lethal intraperitoneal infection with S. "

07/15/2004 - "Fourteen patients with metastatic cancers were vaccinated with hTERT:540-548 emulsified in incomplete Freund's adjuvant. "
01/01/2002 - "Incomplete Freund's adjuvant and C-parvum showed relative weak effects in treating the metastatic tumors."
02/15/1998 - "Vaccination with soluble E7 protein in incomplete Freund's adjuvant likewise induces E7-specific CTL responses associated with tumor protection. "
07/01/1996 - "Vaccination with live Mycobacterium bovis BCG also increased the frequencies of both phenotypes of hsp65-reactive cells equally (to approximately 1:2,500), whereas vaccination procedures that were not protective, with either dead BCG, hsp65 protein in incomplete Freund's adjuvant, or hsp65 mixed with tumor cells, resulted in preferential increase in CD4+ CD8- cells. "
12/01/1976 - "In allogeneic mice, the activity was facilitated slightly by immunization with viable tumor cells or tumor cells in complete Fruend's adjuvant but not with tumor cells in incomplete Freund's adjuvant. "

01/01/2007 - "In this study, we evaluated the efficacy of the natural adjuvant, C3d, versus alum in eliciting an anti-PA humoral response and found that C3d conjugation to PA and emulsion in incomplete Freund's adjuvant (IFA) imparted superior protection from anthrax challenge relative to PA in IFA or PA adsorbed to alum. "

07/01/2005 - "To investigate cellular mechanisms and the role of antigen-presenting cells in regulation of myocarditis, we induced protection against EAM in Lewis rats by administration of S2-16 peptide in incomplete Freund's adjuvant (IFA). "
02/01/2012 - "Myocarditis development was investigated after immunization rats with single subcutaneous injection of cardiac myosin (800 microg/kg) with incomplete Freund's adjuvant (IFA) (M + IFA group). "

10/01/1999 - "Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma."
08/01/2014 - "Thirty-seven participants with stage IIIB-IV melanoma were vaccinated with 6MHP in incomplete Freund's adjuvant. "
07/01/2013 - "We conducted a randomized clinical trial in 45 patients with resected AJCC stage IIB-IV melanoma to characterize cellular and molecular events at sites of immunization with incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA. "
07/01/2010 - "Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine."
07/01/2000 - "Immunization with the modified gp100 melanoma peptide gp100:109-217 (210M) in Incomplete Freund's Adjuvant (IFA) results in the generation of antipeptide and antitumor lymphocytes in the patients' circulation. "